XTL Biopharmaceuticals Ltd

XTLB

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001023549

SEC filings (opens in a new tab)

No open-market purchases or sales by XTL Biopharmaceuticals Ltd insiders were filed in the last 90 days; 3 institutions reported holding it in 13F filings for Q2 2026, worth $20.7K in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding XTL Biopharmaceuticals Ltd changed between Q3 2021 and Q4 2021.

All holders in Q4 2021 All holders in Q3 2021

13F holders of XTLB: Q3 2021 compared with Q4 2021
Measure	Q3 2021	Q4 2021	Change
Holders	6	6	0
Shares	487.4K	472.4K	−15.0K (−3.1%)
Value	$2.13M	$1.31M	−$828.0K (−38.8%)

New holders (1)

Institutions that held XTL Biopharmaceuticals Ltd at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to XTLB in Q4 2021
Institution	Shares	Value	% of portfolio
Tower Research Capital LLC (TRC)	153	$0	0.00%

Sold out (1)

Institutions that held XTL Biopharmaceuticals Ltd at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of XTLB in Q4 2021
Institution	Shares, Q3 2021	Value, Q3 2021
Citadel Advisors LLC	12,801	$56.0K